| NYC Informatics™ |
| Angiotensin-Converting Enzyme Inhibitors (ACEI) and |
| Angiotensin II Receptor Blockers (ARBs) |
| Utilization Evaluation |
| Gender | Group 1 All ACEI/ARBs Utilizers |
Group 2 Diabetes coexisting Hypertension |
Group 3 Not Having Diabetes |
| Female | 18,192 | 1,600 | 14,888 |
| Male | 20,998 | 1,882 | 16,972 |
| 39,190 | 3,482 | 31,860 |
| Note: Group 3 includes the 15,115 members with no HCFA/UB92 claims |
| Data source: Pharmacy, Managed Care and Traditional claims |
| report generated on 14SEP2003 |
| www.nycinformatics.com |